

2023 2 Tier Standard - Keystone First VIP Choice

2023 Step Therapy Criteria

CURRENT AS OF 11/01/2023

anticonvulsant step therapy

Products Affected

- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- ZONISADE SUSPENSION 100 MG/5ML ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of two generic anticonvulsants. Step 2: Once two of the medications listed in Step 1 have been tried, patients can receive therapy with Spritam, Sympazan or Zonisade.
-----------------	--

antidepressant step therapy

Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of two generic antidepressants. Step 2: Once two of the medications listed in step 1 have been tried, patient can receive therapy with Fetzima.
----------	---

brinzolamide step therapy

Products Affected

- *brinzolamide suspension 1 % ophthalmic*

Details

Criteria	Step 1: First line therapy should be a documented trial of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, the patient can receive therapy with brinzolamide.
-----------------	---

combivent step therapy

Products Affected

- COMBIVENT RESPIMAT AEROSOL SOLUTION 20-100 MCG/ACT INHALATION

Details

Criteria	Step 1: First line therapy should be a documented trial of Anoro Ellipta, Bevespi Aerosphere, or Stiolto Respimat. Step 2: Once Anoro Ellipta, Bevespi Aerosphere, or Stiolto Respimat has been tried, patients can receive therapy with Combivent Respimat.
-----------------	--

drizalma and savella step therapy

Products Affected

- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL
- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of generic duloxetine. Step 2: Once generic duloxetine has been tried, patients can receive therapy with Savella.
-----------------	---

febuxostat step therapy

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial of allopurinol tablet. Step 2: Once allopurinol tablet has been tried, patients can receive therapy with Febuxostat.
----------	--

glp-1 agonists

Products Affected

- MOUNJARO SOLUTION PEN-INJECTOR 10 MG/0.5ML SUBCUTANEOUS
- MOUNJARO SOLUTION PEN-INJECTOR 12.5 MG/0.5ML SUBCUTANEOUS
- MOUNJARO SOLUTION PEN-INJECTOR 15 MG/0.5ML SUBCUTANEOUS
- MOUNJARO SOLUTION PEN-INJECTOR 2.5 MG/0.5ML SUBCUTANEOUS
- MOUNJARO SOLUTION PEN-INJECTOR 5 MG/0.5ML SUBCUTANEOUS
- MOUNJARO SOLUTION PEN-INJECTOR 7.5 MG/0.5ML SUBCUTANEOUS
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/3ML SUBCUTANEOUS
- OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 4 MG/3ML SUBCUTANEOUS
- OZEMPIC (2 MG/DOSE) SOLUTION PEN-INJECTOR 8 MG/3ML SUBCUTANEOUS
- RYBELSUS TABLET 14 MG ORAL
- RYBELSUS TABLET 3 MG ORAL
- RYBELSUS TABLET 7 MG ORAL
- TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 3 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 4.5 MG/0.5ML SUBCUTANEOUS
- VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS

Details

Criteria	Step 1: First line therapy should be a documented trial of metformin or a metformin combination product. Step 2: Once metformin or a metformin combination product has been tried, patients can receive therapy with Ozempic, Victoza, Trulicity, Rybelsus, or Mounjaro
-----------------	---

netarsudil step therapy

Products Affected

- RHOPRESSA SOLUTION 0.02 %
OPHTHALMIC
- ROCKLATAN SOLUTION 0.02-0.005 %
OPHTHALMIC

Details

Criteria	Step 1: First line therapy should be a documented trial of latanoprost or travoprost. Step 2: Once latanoprost or travoprost has been tried, patients can receive therapy with Rhopressa or Rocklatan.
-----------------	--

ongentys step therapy

Products Affected

- ONGENTYS CAPSULE 25 MG ORAL
- ONGENTYS CAPSULE 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial of entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, patients can receive therapy with Ogmentys.
-----------------	--

rivastigmine patch step therapy

Products Affected

- *rivastigmine patch 24 hour 13.3 mg/24hr transdermal*
- *rivastigmine patch 24 hour 9.5 mg/24hr transdermal*
- *rivastigmine patch 24 hour 4.6 mg/24hr transdermal*

Details

Criteria	Step 1: First line therapy should be a documented trial of rivastigmine capsule. Step 2: Once rivastigmine capsule has been tried, patients can receive therapy with rivastigmine patches.
-----------------	--

topical immunomodulators step therapy

Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

Details

Criteria	Step 1: First line therapy should be a documented trial of two topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, patients can receive therapy with generic pimecrolimus or generic topical tacrolimus.
-----------------	---

urinary incontinence agents step therapy

Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- *fesoterodine fumarate er tablet extended release 24 hour 4 mg oral*
- *fesoterodine fumarate er tablet extended release 24 hour 8 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*

Details

Criteria	
	Step 1: First line therapy should be a documented trial of oxybutynin, oxybutynin ER, trospium, tolterodine, tolterodine ER, or solifenacin. Step 2: Second line therapy should be trospium ER, darifenacin ER or fesoterodine ER

Index

B

brinzolamide suspension 1 % ophthalmic... 3

C

COMBIVENT RESPIMAT AEROSOL
SOLUTION 20-100 MCG/ACT
INHALATION..... 4

D

darifenacin hydrobromide er tablet extended
release 24 hour 15 mg oral..... 12
darifenacin hydrobromide er tablet extended
release 24 hour 7.5 mg oral..... 12

F

febuxostat tablet 40 mg oral..... 6
febuxostat tablet 80 mg oral..... 6
fesoterodine fumarate er tablet extended
release 24 hour 4 mg oral..... 12
fesoterodine fumarate er tablet extended
release 24 hour 8 mg oral..... 12
FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 120 MG ORAL ... 2
FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 20 MG ORAL 2
FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 40 MG ORAL 2
FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 80 MG ORAL 2
FETZIMA TITRATION CAPSULE ER 24
HOUR THERAPY PACK 20 & 40 MG
ORAL..... 2

M

MOUNJARO SOLUTION PEN-INJECTOR
10 MG/0.5ML SUBCUTANEOUS 7
MOUNJARO SOLUTION PEN-INJECTOR
12.5 MG/0.5ML SUBCUTANEOUS 7
MOUNJARO SOLUTION PEN-INJECTOR
15 MG/0.5ML SUBCUTANEOUS 7
MOUNJARO SOLUTION PEN-INJECTOR
2.5 MG/0.5ML SUBCUTANEOUS 7
MOUNJARO SOLUTION PEN-INJECTOR
5 MG/0.5ML SUBCUTANEOUS 7
MOUNJARO SOLUTION PEN-INJECTOR
7.5 MG/0.5ML SUBCUTANEOUS 7

O

ONGENTYS CAPSULE 25 MG ORAL 9
ONGENTYS CAPSULE 50 MG ORAL 9

OZEMPIC (0.25 OR 0.5 MG/DOSE)
SOLUTION PEN-INJECTOR 2
MG/1.5ML SUBCUTANEOUS 7
OZEMPIC (0.25 OR 0.5 MG/DOSE)
SOLUTION PEN-INJECTOR 2
MG/3ML SUBCUTANEOUS 7
OZEMPIC (1 MG/DOSE) SOLUTION
PEN-INJECTOR 2 MG/1.5ML
SUBCUTANEOUS..... 7
OZEMPIC (1 MG/DOSE) SOLUTION
PEN-INJECTOR 4 MG/3ML
SUBCUTANEOUS..... 7
OZEMPIC (2 MG/DOSE) SOLUTION
PEN-INJECTOR 8 MG/3ML
SUBCUTANEOUS..... 7

P

pimecrolimus cream 1 % external..... 11

R

RHOPRESSA SOLUTION 0.02 %
OPHTHALMIC 8
rivastigmine patch 24 hour 13.3 mg/24hr
transdermal..... 10
rivastigmine patch 24 hour 4.6 mg/24hr
transdermal..... 10
rivastigmine patch 24 hour 9.5 mg/24hr
transdermal..... 10
ROCKLATAN SOLUTION 0.02-0.005 %
OPHTHALMIC 8
RYBELSUS TABLET 14 MG ORAL 7
RYBELSUS TABLET 3 MG ORAL 7
RYBELSUS TABLET 7 MG ORAL 7

S

SAVELLA TABLET 100 MG ORAL..... 5
SAVELLA TABLET 12.5 MG ORAL..... 5
SAVELLA TABLET 25 MG ORAL..... 5
SAVELLA TABLET 50 MG ORAL..... 5
SAVELLA TITRATION PACK 12.5 & 25
& 50 MG ORAL 5
SPRITAM TABLET DISINTEGRATING
SOLUBLE 1000 MG ORAL 1
SPRITAM TABLET DISINTEGRATING
SOLUBLE 250 MG ORAL 1
SPRITAM TABLET DISINTEGRATING
SOLUBLE 500 MG ORAL 1

SPRITAM TABLET DISINTEGRATING
 SOLUBLE 750 MG ORAL 1
 SYMPAZAN FILM 10 MG ORAL..... 1
 SYMPAZAN FILM 20 MG ORAL..... 1
 SYMPAZAN FILM 5 MG ORAL..... 1
T
 tacrolimus ointment 0.03 % external 11
 tacrolimus ointment 0.1 % external 11
 trospium chloride er capsule extended
 release 24 hour 60 mg oral..... 12
 TRULICITY SOLUTION PEN-INJECTOR
 0.75 MG/0.5ML SUBCUTANEOUS 7

TRULICITY SOLUTION PEN-INJECTOR
 1.5 MG/0.5ML SUBCUTANEOUS 7
 TRULICITY SOLUTION PEN-INJECTOR
 3 MG/0.5ML SUBCUTANEOUS 7
 TRULICITY SOLUTION PEN-INJECTOR
 4.5 MG/0.5ML SUBCUTANEOUS 7
V
 VICTOZA SOLUTION PEN-INJECTOR
 18 MG/3ML SUBCUTANEOUS 7
Z
 ZONISADE SUSPENSION 100 MG/5ML
 ORAL..... 1